Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Can we prevent stent restenosis after coronary stent implantation
PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
PCI VS CABG JOURNAL REVIEW
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
DEFER STUDY: 5-YEAR FOLLOW-UP A Multicenter Randomized Study
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Decision Models Based on Individual Patient and Summary Data Mark Sculpher Neil Hawkins Centre for Health Economics, University of York Workshop: Towards.
Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Journal Club Jeffrey P Schaefer, MD April 16, 2007.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Total Occlusion Study of Canada (TOSCA-2) Trial
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
Section 5: Intervention and drug therapy
American College of Cardiology Presented by Dr. Stephan Windecker
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The European Society of Cardiology Presented by RJ De Winter
Global Registry of Acute Coronary Events: GRACE
LRC-CPPT and MRFIT Content Points:
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Adjunctive Therapies in the Treatment of Acute Coronary Syndromes
Atlantic Cardiovascular Patient Outcomes Research Team
The American College of Cardiology Presented by Dr. A. Abazid
Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.
Presentation transcript:

Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes G. Katritsis, MD, PhD; John P.A. Ioannidis, MD

PCI vs. Conservative Therapy: Background The potential benefits of percutaneous coronary intervention (PCI) in the management of stable patients with coronary artery disease (CAD) in nonacute settings have been debated for more than a decade.The potential benefits of percutaneous coronary intervention (PCI) in the management of stable patients with coronary artery disease (CAD) in nonacute settings have been debated for more than a decade. Although PCI has been shown to improve symptoms compared with conservative treatment in patients with stable CAD, there is limited evidence on the effect of PCI with regards to death, myocardial infarction (MI), and subsequent revascularization.Although PCI has been shown to improve symptoms compared with conservative treatment in patients with stable CAD, there is limited evidence on the effect of PCI with regards to death, myocardial infarction (MI), and subsequent revascularization. The results of a meta-analysis from 11 studies in patients with angiographically documented coronary artery stenosis in nonacute CAD settings are reported.The results of a meta-analysis from 11 studies in patients with angiographically documented coronary artery stenosis in nonacute CAD settings are reported. The potential benefits of percutaneous coronary intervention (PCI) in the management of stable patients with coronary artery disease (CAD) in nonacute settings have been debated for more than a decade.The potential benefits of percutaneous coronary intervention (PCI) in the management of stable patients with coronary artery disease (CAD) in nonacute settings have been debated for more than a decade. Although PCI has been shown to improve symptoms compared with conservative treatment in patients with stable CAD, there is limited evidence on the effect of PCI with regards to death, myocardial infarction (MI), and subsequent revascularization.Although PCI has been shown to improve symptoms compared with conservative treatment in patients with stable CAD, there is limited evidence on the effect of PCI with regards to death, myocardial infarction (MI), and subsequent revascularization. The results of a meta-analysis from 11 studies in patients with angiographically documented coronary artery stenosis in nonacute CAD settings are reported.The results of a meta-analysis from 11 studies in patients with angiographically documented coronary artery stenosis in nonacute CAD settings are reported. Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111:

PCI vs. Conservative Therapy: Study Design  Primary Endpoint: Death, Cardiac Death or nonfatal MI, CABG, and PCI during follow-up (in the target vessel or other vessel/segment). - All data used pertained to the longest follow-up available per outcome from each study  Primary Endpoint: Death, Cardiac Death or nonfatal MI, CABG, and PCI during follow-up (in the target vessel or other vessel/segment). - All data used pertained to the longest follow-up available per outcome from each study PCIn=1476PCIn=1476 Conservative Therapy n=1474 n= patients from randomized trials comparing coronary revascularization by PCI versus conservative medical therapy for treatment of patients with CAD documented by angiographic evidence of stenosis of 1 or more coronary vessels Meta-Analysis Mean age range years, predominantly or exclusively male population, mean follow-up in 5 trials (with 1790 patients) exceeded 2 years, more limited follow-up data available in other 6 trials (1160 patients), no trial used DES 2950 patients from randomized trials comparing coronary revascularization by PCI versus conservative medical therapy for treatment of patients with CAD documented by angiographic evidence of stenosis of 1 or more coronary vessels Meta-Analysis Mean age range years, predominantly or exclusively male population, mean follow-up in 5 trials (with 1790 patients) exceeded 2 years, more limited follow-up data available in other 6 trials (1160 patients), no trial used DES Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111:

PCI vs. Conservative Therapy: Primary Endpoint There were a total of 196 deaths, 235 patients had cardiac death or MI, 153 patients had nonfatal MIs, 215 patients underwent CABG, and 462 had PCI during follow-up.There were a total of 196 deaths, 235 patients had cardiac death or MI, 153 patients had nonfatal MIs, 215 patients underwent CABG, and 462 had PCI during follow-up. Despite some differences, there was no statistically significant between-study heterogeneity for death, cardiac death or MI, nonfatal MI, and need for CABG; thus, random and fixed effects estimates were very similar for these outcomes.Despite some differences, there was no statistically significant between-study heterogeneity for death, cardiac death or MI, nonfatal MI, and need for CABG; thus, random and fixed effects estimates were very similar for these outcomes. Number events per treatment group (# patients) # patients Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111:

There was large between-study heterogeneity in the risk ratios for PCI during follow-up.There was large between-study heterogeneity in the risk ratios for PCI during follow-up. There was no difference shown in the summary estimates between PCI and the conservative group in the mortality risk.There was no difference shown in the summary estimates between PCI and the conservative group in the mortality risk. The 95% confidence intervals excluded relative risk differences of 28%.The 95% confidence intervals excluded relative risk differences of 28%. PCI vs. Conservative Therapy: Risk Ratio for Death Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111:

PCI vs. Conservative Therapy: Risk Ratio for Cardiac Death or MI There was a trend for more cardiac deaths or MIs (Figure B), especially nonfatal MIs (Figure C) in patients who underwent PCI.There was a trend for more cardiac deaths or MIs (Figure B), especially nonfatal MIs (Figure C) in patients who underwent PCI. The point estimate suggests approximately a 30% increase in the relative risk of nonfatal MI with PCI.The point estimate suggests approximately a 30% increase in the relative risk of nonfatal MI with PCI.

Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Risk Ratio for CABG Between the two compared treatment strategies, there was no difference in the need for CABG.Between the two compared treatment strategies, there was no difference in the need for CABG. The 95% confidence intervals also excluded differences in the relative risk exceeding 20% in favor of PCI and 33% in favor of conservative treatment.The 95% confidence intervals also excluded differences in the relative risk exceeding 20% in favor of PCI and 33% in favor of conservative treatment.

Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Risk Ratio for PCI during follow-up Although there was no overall difference in the risk for PCI during follow-up, the random effects 95% confidence intervals were more substantial given the considerable variability between study heterogeneity.Although there was no overall difference in the risk for PCI during follow-up, the random effects 95% confidence intervals were more substantial given the considerable variability between study heterogeneity.

Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Sub Group Analysis Subgroup analyses showed that availability of stents did not make a substantial difference for any of the 5 end points.Subgroup analyses showed that availability of stents did not make a substantial difference for any of the 5 end points. In trials with follow-up exceeding 2 years, there were no differences between PCI and conservative treatments, with RR estimates very close to 1.00 for all outcomes.In trials with follow-up exceeding 2 years, there were no differences between PCI and conservative treatments, with RR estimates very close to 1.00 for all outcomes. Trials with more limited follow-up suggested an increase in deaths, MI, and nonfatal MI in PCI-treated patients, and the difference reached formal statistical significance for cardiac death or MI, with almost a doubling of risk conferred by PCI; however, the CIs overlapped with the results from longer term trials.Trials with more limited follow-up suggested an increase in deaths, MI, and nonfatal MI in PCI-treated patients, and the difference reached formal statistical significance for cardiac death or MI, with almost a doubling of risk conferred by PCI; however, the CIs overlapped with the results from longer term trials.

Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Limitations Data were not available consistently across these trials to separate procedure based infarctions from subsequent MI.Data were not available consistently across these trials to separate procedure based infarctions from subsequent MI. It is unlikely that myocardial enzymes were routinely checked after PCI so that risk of post PCI MI may have been underestimated.It is unlikely that myocardial enzymes were routinely checked after PCI so that risk of post PCI MI may have been underestimated. Also, minor procedure-related infarctions without definitive ECG changes may have been largely underreported in the PCI arms.Also, minor procedure-related infarctions without definitive ECG changes may have been largely underreported in the PCI arms. Several of these trials were conducted in the time period before the routine use of stents in clinical practice.Several of these trials were conducted in the time period before the routine use of stents in clinical practice. The disease background of the patients included was different across trials.The disease background of the patients included was different across trials. Data were not available consistently across these trials to separate procedure based infarctions from subsequent MI.Data were not available consistently across these trials to separate procedure based infarctions from subsequent MI. It is unlikely that myocardial enzymes were routinely checked after PCI so that risk of post PCI MI may have been underestimated.It is unlikely that myocardial enzymes were routinely checked after PCI so that risk of post PCI MI may have been underestimated. Also, minor procedure-related infarctions without definitive ECG changes may have been largely underreported in the PCI arms.Also, minor procedure-related infarctions without definitive ECG changes may have been largely underreported in the PCI arms. Several of these trials were conducted in the time period before the routine use of stents in clinical practice.Several of these trials were conducted in the time period before the routine use of stents in clinical practice. The disease background of the patients included was different across trials.The disease background of the patients included was different across trials.

Additionally, patient populations differed across trials with respect to intensity of angina symptoms, functional demonstration of ischemia, and angiographic extent of CAD.Additionally, patient populations differed across trials with respect to intensity of angina symptoms, functional demonstration of ischemia, and angiographic extent of CAD. The included trials did not routinely use the full spectrum of conservative interventions currently available for CAD management.The included trials did not routinely use the full spectrum of conservative interventions currently available for CAD management. Overall the varying and potentially suboptimal medical management across trials is a limitation of the meta- analysis; however, one would expect better outcomes if the management were optimized.Overall the varying and potentially suboptimal medical management across trials is a limitation of the meta- analysis; however, one would expect better outcomes if the management were optimized. Lastly, the present meta-analysis did not consider the option of CABG in patients with stable chronic CAD and preserved LV function.Lastly, the present meta-analysis did not consider the option of CABG in patients with stable chronic CAD and preserved LV function. Additionally, patient populations differed across trials with respect to intensity of angina symptoms, functional demonstration of ischemia, and angiographic extent of CAD.Additionally, patient populations differed across trials with respect to intensity of angina symptoms, functional demonstration of ischemia, and angiographic extent of CAD. The included trials did not routinely use the full spectrum of conservative interventions currently available for CAD management.The included trials did not routinely use the full spectrum of conservative interventions currently available for CAD management. Overall the varying and potentially suboptimal medical management across trials is a limitation of the meta- analysis; however, one would expect better outcomes if the management were optimized.Overall the varying and potentially suboptimal medical management across trials is a limitation of the meta- analysis; however, one would expect better outcomes if the management were optimized. Lastly, the present meta-analysis did not consider the option of CABG in patients with stable chronic CAD and preserved LV function.Lastly, the present meta-analysis did not consider the option of CABG in patients with stable chronic CAD and preserved LV function. Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Limitations (cont.)

Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD.Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD. A trend for increased risk of MI in patients undergoing PCI was observed, which may reflect the risk inherent in the invasive procedure itself.A trend for increased risk of MI in patients undergoing PCI was observed, which may reflect the risk inherent in the invasive procedure itself. Although early literature suggests that PCI may cause an increased need for CABG, there was no evidence for an increased need for CABG in the PCI group compared with the conservative strategy group.Although early literature suggests that PCI may cause an increased need for CABG, there was no evidence for an increased need for CABG in the PCI group compared with the conservative strategy group. Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD.Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD. A trend for increased risk of MI in patients undergoing PCI was observed, which may reflect the risk inherent in the invasive procedure itself.A trend for increased risk of MI in patients undergoing PCI was observed, which may reflect the risk inherent in the invasive procedure itself. Although early literature suggests that PCI may cause an increased need for CABG, there was no evidence for an increased need for CABG in the PCI group compared with the conservative strategy group.Although early literature suggests that PCI may cause an increased need for CABG, there was no evidence for an increased need for CABG in the PCI group compared with the conservative strategy group. Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Summary

Similarly, there was no difference in the risk of requiring PCI during follow-up with interventional versus conservative therapy; however, there was considerable variability in this outcome across trials. One possible explanation for this heterogeneity is that although indications for CABG are relatively clear-cut, indications for PCI are more subjective, meaning that different investigators and sites may have had different biases toward the use of PCI during follow-up based on whether or not it was used prior.Similarly, there was no difference in the risk of requiring PCI during follow-up with interventional versus conservative therapy; however, there was considerable variability in this outcome across trials. One possible explanation for this heterogeneity is that although indications for CABG are relatively clear-cut, indications for PCI are more subjective, meaning that different investigators and sites may have had different biases toward the use of PCI during follow-up based on whether or not it was used prior. PCI vs. Conservative Therapy: Summary (cont.)

Importantly, even when analyses were limited to studies that used stents, this meta-analysis found no evidence of superiority for the PCI strategy.Importantly, even when analyses were limited to studies that used stents, this meta-analysis found no evidence of superiority for the PCI strategy. In conclusion, in the absence of acute coronary syndromes, for patients with chronic CAD and good LV function, PCI does not confer any clear benefit in terms of long-term hard clinical outcomes compared with conservative medical therapy.In conclusion, in the absence of acute coronary syndromes, for patients with chronic CAD and good LV function, PCI does not confer any clear benefit in terms of long-term hard clinical outcomes compared with conservative medical therapy. Randomized trials in the modern era of pharmacotherapy and new device interventions is lacking.Randomized trials in the modern era of pharmacotherapy and new device interventions is lacking. Importantly, even when analyses were limited to studies that used stents, this meta-analysis found no evidence of superiority for the PCI strategy.Importantly, even when analyses were limited to studies that used stents, this meta-analysis found no evidence of superiority for the PCI strategy. In conclusion, in the absence of acute coronary syndromes, for patients with chronic CAD and good LV function, PCI does not confer any clear benefit in terms of long-term hard clinical outcomes compared with conservative medical therapy.In conclusion, in the absence of acute coronary syndromes, for patients with chronic CAD and good LV function, PCI does not confer any clear benefit in terms of long-term hard clinical outcomes compared with conservative medical therapy. Randomized trials in the modern era of pharmacotherapy and new device interventions is lacking.Randomized trials in the modern era of pharmacotherapy and new device interventions is lacking. Katritsis DG & Ioannidis J.P.A., Circulation 2005; 111: PCI vs. Conservative Therapy: Summary (cont.)